Physician profile
Anthony Marano
NPI 1841202777
$10,623.93
in general payments reported to CMS, 2019-2025
57 companies · $1,745 in 2025
The $1,745 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,310 · 2020: $1,055 · 2021: $1,003 · 2022: $1,741 · 2023: $2,564 · 2024: $1,207 · 2025: $1,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,580 · Travel and Lodging: $903 · Education: $32.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,579.70 |
| Travel and Lodging | $903.32 |
| Education | $32.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,008.48 | 2020-2025 | Optis, Cardiomems, Dragonfly Opstar |
| Janssen Pharmaceuticals, INC | $1,374.34 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $990.97 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $841.50 | 2019-2024 | Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd, Watchman Flx |
| Pfizer INC. | $585.06 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $581.99 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $514.79 | 2019-2025 | |
| Aop Health US, LLC | $394.21 | 2025 | Rapiblyk |
| Astrazeneca Pharmaceuticals LP | $312.47 | 2019-2024 | Brilinta, Andexxa, Lokelma |
| Novo Nordisk INC | $260.72 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Philips North America LLC | $189.97 | 2022-2025 | (5091) Amb Mon & Diag Und, (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided |
| Amgen INC. | $168.52 | 2019-2024 | Repatha |
| Abiomed | $166.15 | 2024-2025 | Impella |
| Siemens Medical Solutions USA, INC. | $156.30 | 2019-2022 | |
| Lilly USA, LLC | $144.75 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Marano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.